HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

zafirlukast (Accolate)

Subscribe to New Research on zafirlukast

a leukotriene D4 receptor antagonist

Also Known As:

Accolate; 4-(5-cyclopentyloxycarbonylamino-2-methylindol-3-yl-methyl)-3-methoxy-N-O-tolylsulfonylbenzamide; Aeronix; AstraZeneca brand of zafirlukast; ICI 204,219; ICI 204219; ICI-204219; Menarini brand of zafirlukast; Novartis brand of zafirlukast; Olmoran; Zeneca brand of zafirkulast

Networked: 229 relevant articles (52 outcomes, 58 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 58
- Hydrocarbons: 412
  - Cyclic Hydrocarbons: 3
    - Aromatic Hydrocarbons: 132
      - Benzene Derivatives: 13
        Toluene: 648
        Tosyl Compounds
        zafirlukast: 229
- Sulfur Compounds: 135
  - Sulfones: 136
    - Tosyl Compounds
      - zafirlukast: 229

Experts

1.	Centanni, S: 4 articles (06/2003 - 01/2000)
2.	Kalberg, C: 4 articles (08/2001 - 06/2000)
3.	Edwards, L: 4 articles (07/2001 - 06/2000)
4.	Antileukotriene Working Group: 4 articles (06/2001 - 06/2001)
5.	Kamei, Chiaki: 3 articles (11/2007 - 01/2004)
6.	Allegra, L: 3 articles (05/2003 - 01/2000)
7.	Nathan, R A: 3 articles (08/2001 - 06/2001)
8.	Yancey, S W: 3 articles (07/2001 - 01/2001)
9.	Rickard, K A: 3 articles (07/2001 - 06/2000)
10.	Rickard, K: 3 articles (07/2001 - 11/2000)

Related Diseases

1.	Asthma (Bronchial Asthma) 01/01/2014 - "It has proven efficacy in reducing asthma exacerbations, but the effect size of zafirlukast for asthma exacerbations of various severity is not systematically explored. " 04/01/2002 - "Furthermore, good efficacy of zafirlukast was confirmed in clinical trials in adult bronchial asthma patients. " 04/01/2000 - "This study has demonstrated that zafirlukast offers significant protection against cold air-induced bronchoconstriction in asthma. " 01/01/2008 - "In Group I, zafirlukast significantly improved morning PEF and FEV1compared to placebo (p < 0.01), and reduced morning waking with asthma from baseline after two weeks (p < 0.05). " 03/01/2001 - "In conclusion, we demonstrate the efficacy of zafirlukast in asthma therapy particularly for those patients who are younger and have better pulmonary function. "
2.	Contracture 10/01/2012 - "The present study suggests that zafirlukast may be effective in reducing breast capsule distortion in patients with long-standing contracture, though reduced capsular contracture values are strictly related to the duration of drug intake." 01/01/2005 - "Zafirlukast appears effective in treating early capsular contracture after primary submuscular breast augmentation using saline-filled, smooth-walled implants. " 07/01/2007 - "Effects of zafirlukast on capsular contracture: controlled study measuring the mammary compliance." 01/01/2005 - "The purpose of this study was to prospectively examine a single surgeon's experience using zafirlukast in the treatment of capsular contracture in primary, submuscular breast augmentation with saline-filled, smooth-walled implants. " 10/01/2012 - "Effects of zafirlukast on capsular contracture: long-term results."
3.	Chronic Obstructive Pulmonary Disease (COPD) 01/01/2000 - "Lung function improvement in smokers suffering from COPD with zafirlukast, a CysLT(1)-receptor antagonist." 05/01/2013 - "The aim of our study was to evaluate the effects of Zafirlukast improvement of lung function in patients with COPD. " 01/01/2003 - "Through a randomised, double-blind, crossover and placebo-controlled study, we assessed the short-term effects of zafirlukast in patients with severe COPD. " 05/01/2013 - "Results showed that Zafirlukast has no considerable bronchodilatory effect in COPD. " 03/01/2003 - "Zafirlukast may play a role as an alternative to decrease PAP in COPD patients."
4.	Rhinitis 06/01/2003 - "At the end of the study period, zafirlukast significantly reduced asthma and rhinitis symptoms (P< or =0.05); FEV(1) values were unchanged (P=0.10), whereas nasal resistances showed a decrease following treatment (P=0.01). " 09/01/1997 - "All available published articles describing double-blind, placebo-controlled trials of both oral and aerosol zafirlukast in patients with asthma or rhinitis were reviewed. " 06/01/2003 - "These positive effects suggest that zafirlukast may be usefully employed in the treatment of both bronchial asthma, as previously demonstrated, and allergic rhinitis." 06/01/2003 - "Effects of zafirlukast on bronchial asthma and allergic rhinitis." 07/01/2007 - "We performed a placebo-controlled study, with 120 persistent, moderate to severe allergic rhinitis patients randomly selected to receive the different treatments for 4 weeks: no treatment, 10 mg of cetirizine once per day, 20 mg of zafirlukast once per day, 20 mg of cafirlukast twice per day, a combination of 20 mg of zafirlukast and 10 mg of cetirizine once per day, or a combination of 20 mg of zafirlukast twice per day and 10 mg cetirizine once per day. "
5.	Bronchial Spasm 06/01/1998 - "In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma. " 05/11/2001 - "A recent clinical study showed that combined antagonists loratadine (H1) and zafirlukast (CysLT1) were more effective against allergic bronchospasms than either drug alone. " 04/01/1990 - "Aerosol ovalbumin antigen-induced bronchospasm in guinea pigs was both inhibited and reversed by ICI 204,219. "

Related Drugs and Biologics

1.	zafirlukast (Accolate)
2.	Leukotriene Receptors (Leukotriene Receptor)
3.	fluticasone (Cutivate)
4.	zileuton (Zyflo)
5.	salmeterol (Serevent)
6.	Loratadine (Alavert)
7.	Adrenal Cortex Hormones (Corticosteroids)
8.	montelukast (Singulair)
9.	leukotriene D4 receptor (cysteinyl leukotriene receptor)
10.	Leukotriene Antagonists (Leukotriene Receptor Antagonists)

Related Therapies and Procedures

1.	Topical Administration
2.	Drug Therapy (Chemotherapy)
3.	Aftercare (After-Treatment)
4.	Therapeutics
5.	Off-Label Use